生脉胶囊联合化疗治疗晚期肺腺癌临床研究

Clinical Study on Shengmai Capsules Combined with Chemotherapy for Advanced Lung Adenocarcinoma

目的:观察生脉胶囊联合化疗治疗晚期肺腺癌的临床疗效。方法:选择晚期肺腺癌患者60例,按照随机数字表法分为对照组27例和观察组33例。对照组给予培美曲塞联合顺铂方案化疗,观察组在对照组的基础上给予生脉胶囊治疗。21 d为1个化疗周期,共连续治疗3个周期。评估2组治疗前后生存质量、血清癌胚抗原(CEA)水平、毒副反应和临床疗效。结果:观察组有效率为60.61%,对照组为62.96%,2组比较,差异无统计学意义(P>0.05);观察组疾病控制率为90.91%,对照组为88.89%,2组比较,差异无统计学意义(P>0.05)。治疗前,2组卡氏功能状态评分(KPS)比较,差异无统计学意义(P>0.05);治疗后,观察组KPS评分较治疗前升高,且高于对照组,但差异均无统计学意义(P>0.05)。治疗前,2组血清CEA水平比较,差异无统计学意义(P>0.05)。治疗后,2组CEA水平均较治疗前降低(P<0.05),且观察组CEA水平低于对照组(P<0.05)。治疗期间,观察组毒副反应总发生率为42.42%,对照组为77.78%,2组比较,差异无统计学意义(P>0.05)。结论:生脉胶囊联合培美曲塞+顺铂方案治疗晚期肺腺癌患者虽不能明显提高临床疗效,但可下调CEA水平,有效改善患者生活质量,且毒副反应相对较少。

Objective:To observe the clinical effect of the therapy of Shengmai capsules combined with chemotherapy on advanced lung adenocarcinoma.Methods:A total of 60 patients with advanced lung adenocarcinoma were selected and divided into the control group and the observation group according to the random number table method,with 27 and 33 cases in each group respectively.The control group was given chemotherapy of pemetrexed combined with cisplatin,and the observation group was additionally given Shengmai capsules based on the treatment of the control group.Both groups were continuously treated for three chemotherapy cycles,21 days being a cycle.Before and after treatment,the quality of life which was valued,level of serum carcinoembryonic antigen(CEA),toxicity and clinical effects in the two groups were evaluated.Results:The clinical effective rate was 60.61%in the observation group and 62.96%in the control group,there being no significance in the difference(P>0.05).The disease control rate was 90.91%in the observation group and 88.89%in the control group,there being no significance in the difference(P>0.05).Before treatment,there was no significant difference being found in the comparison of KPS scores between the two groups(P>0.05);after treatment,the KPS scores in the observation group was increased when compared with that before treatment(P<0.05),and was higher than that in the control group after treatment(P<0.05).Before treatment,there was no significant difference being found in the comparison of level of serum CEA between the two groups(P>0.05).After treatment,the CEA levels in both groups were decreased when compared with those before treatment(P<0.05),and the CEA level in the observation group was lower than that in control group(P<0.05).During treatment,the incidence of adverse reactions was 42.42%in the observation group,and77.78%in the control group,there being no significance in the difference(P>0.05).Conclusion:The therapy of Shengmai capsules combined with pemetrexed and cisplatin regimen for patients with advanced lung adenocarcinoma is unable to significantly improve the clinical effect,but can reduce the CEA level,effectively improve the quality of life of patients,and does not increase the toxicity of treatment.